Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Investor Presentation (August 2026)
40 slides from Arovella Therapeutics's investor presentation, August 2026
Slide 1: Corporate Presentation
ASX:ALA Corporate Presentation August 2026
Slide 2: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. 4. Whilst this presentation is based on information from sources which are considered The presentation is not intended to be comprehensive or provide all information reliable, no representation or warr
Slide 3: Arovella's Investment Highlights
Arovella’s Investment Highlights CAR-iNKT platform designed to support multiple future therapies Structurally differentiated next-generation cell therapy Near-term clinical validation Platform scalability Pipeline expansion • FDA IND accepted • Off-the-shelf manufacturing • Blood cancers • Phase 1 e
Slide 4: Strong Leadership Team
Strong Leadership Team SENIOR MANAGEMENT TEAM Dr Nicole van der Weerden Dr Robson Dossa Dr Michelle Ferguson Jacqueline Cumming ACTING CHIEF EXECUTIVE OFFICER VP MANUFACTURING & QUALITY SENIOR DIRECTOR RESEARCH & SENIOR DIRECTOR CLINICAL DEVELOPMENT DEVELOPMENT Drug development, regulatory, Cell the
Slide 5: Financial overview
Financial overview Financial Snapshot ASX CODE ALA ALA Price and Volume - 12 Months1 Market capitalisation1 $78.58 million $0.15 Shares on issue 1,208.8 million 40,000,000 $0.12 52-week low / high $0.059 / $0.100 Cash Balance (30 June 2026) $14.4 million 30,000,000 $0.09 Major Shareholders 20,000,00
Slide 6: About CAR-T cells
About CAR-T cells 6
Slide 7: How traditional CAR-T cell therapies work
How traditional CAR-T cell therapies work Effective, but patient-specific, time-intensive and operationally complex T cells = immune cell T cells are a common type of immune cell that fight infections and can help fight cancer. T cells from patient ‘reprogrammed’ Collect patient T cells engineer t
Slide 8: Cell Therapy has revolutionised blood cancer treatment
Cell Therapy has revolutionised blood cancer treatment CAR-T therapies have demonstrated curative potential in blood cancers Cure Product Approval Year 2025 Revenue CAR-T cells have demonstrated ability to 2022 US$1.9 bil3 cure haematological cancers 2017 US$1.5 bil4 Strong 2021 US$1.36 bil5 Sales T
Slide 9: CAR-T technology challenges and ALA's off-the-shelf solution
CAR-T technology challenges ALA’s off-the-shelf Only treats the patient who supplied the T cells solution: Manufacturing & supply chain costs high, failures T cell can occur Each manufacturing T cell batch is patient-specific T cells can be compromised by disease T cell Limited centres can collect a
Slide 10: Introducing invariant Natural Killer T (iNKT) cells
Introducing invariant Natural Killer T (iNKT) cells Bridging the innate and adaptive immune system Innate Immunity Adaptive Immunity ASX:ALA 10
Slide 11: iNKT cells represent a next-generation cell therapy
iNKT cells represent a next-generation cell therapy Properties make them ideal for use in cell therapy Strong safety profile Invariant receptor recognizes the same molecule (CD1d) in all people Innate Don’t cause graft versus host disease (GvHD)6 Immunity Front line of the human immune system
Slide 12: CAR-iNKT cells – a differentiated immune cell
CAR-iNKT cells – a differentiated immune cell Unique biology with potential to overcome core limitations of CAR-T Multiple ways to attack tumours ALLOGENEIC WITHOUT GENE EDITING Off-the-shelf solution; no gene editing required (preserves cell fitness) MULTIPLE WAYS TO KILL CANCER CELLS Reduces the l
Slide 13: Overcoming limitations of existing cell therapies
Overcoming limitations of existing cell therapies CAR-iNKT cells are uniquely positioned for cell therapy applications Modality Key Limitations Arovella CAR-iNKT Advantage Autologous CAR-T Relies on fitness of patient’s own T cells Healthy donor cells with better fitness Complex, costly manufa
Slide 14: World-class CAR-iNKT manufacturing platform
World-class CAR-iNKT manufacturing platform Semi-automated process suitable for large-scale and late-phase clinical development Arovella Manufacturing Platform Isolate iNKT cells Expand to grow billions of CAR-iNKT cells Collect Healthy Engineer iNKT cells to Vial and freeze Donor Blood produce CARs
Slide 15: One platform: three value-creation pathways
One platform: three value-creation pathways Value creation via three workstreams Core platform: healthy-donor iNKT cells + modular CAR backbone + scalable manufacturing Blood cancer validation -> solid-tumour expansion -> autoimmunity expansion CD19+ blood CLDN18.2+ solid CD19+ autoimmune cancers tu
Slide 16: ALA-101 (CAR19-iNKT cells)
ALA-101 (CAR19-iNKT cells) A next generation off-the-shelf cell therapy for CD19 expressing cancers 16
Slide 17: ALA-101: an off-the-shelf solution for CD19+ blood cancers
ALA-101: an off-the-shelf solution for CD19+ blood cancers Phase 1 first-in-human study expected to commence next month Validated target with potential for FDA IND accepted for indication expansion CD19+ lymphomas and Possibility to expand into autoimmunity if phase 1 ALA-101 (CD19 CAR-iNKT) trial s
Slide 18: ALA-101 manufacturing process highly reproducible
ALA-101 manufacturing process highly reproducible Consistently produces highly potent drug product Killing of CD19+ Tumour Cells Robust CAR-iNKT 100 ALA-101 (CD19 CAR-iNKT) Process Development scale batch 1 manufacturing platform 80 Process Development scale batch 2 Cytotoxicity (%) delivers consist
Slide 19: ALA-101 Manufacturing Platform
ALA-101 Manufacturing Platform Batches consistently meet pre-specified release specifications >80 Clinical doses per batch at the planned starting dose* >99% iNKT Purity ALA-101 (CD19 CAR-iNKT) 99.6% mean (range 99.2–100.0%) ~23 Manufacturing duration from donor cells to cryopreserved drug product d
Slide 20: Potent activity in aggressive tumour model
Potent activity in aggressive tumour model Significantly enhances survival and reduces tumour burden Survival of ALA-101-treated mice in Raji lymphoma anti-tumour ALA-101 demonstrates efficacy model robust dose-dependent 100 PBS **** activity in an aggressive ALA-101 (1.7M) *** Overall Survival (%)
Slide 21: Taking ALA-101 into first-in-human trials
Taking ALA-101 into first-in-human trials ALA is progressing towards its ALA-101-001 phase 1 study Expected First patient dosed with ALA-101 September 2026 First patient successfully enrolled into the study First patient screened for participation in the study ALA-101 (CD19 CAR-iNKT) Complete clinic
Slide 22: ALA-101-001 Phase 1 study; Blood Cancer
ALA-101-001 Phase 1 study; Blood Cancer Study population Adults with relapsed/refractory NHL (DLBCL • FL • MZL • MCL) CD19-positive B cell cancers Leukaemia (CLL • HCL) Patient journey 1. Screening 2. Lymphodepletion 3. ALA-101 infusion 4. On-study follow-up 5. Long-term follow-up Confirm eligibilit
Slide 23: The autoimmune opportunity for ALA-101
The autoimmune opportunity for ALA-101 CD19 cell therapy is emerging as a potential new approach to treat autoimmune disease ALA-101 clinical trial The problem in blood cancers Serious autoimmune diseases such as lupus, myositis, stiff person syndrome, generalized myasthenia gravis, and systemic scl
Slide 24: iNKT cells to target solid tumours
iNKT cells to target solid tumours Arovella is implementing its strategy to target and kill solid tumours – 90% of newly diagnosed cancer cases15 24
Slide 25: iNKT cells are well placed to tackle solid tumours
iNKT cells are well placed to tackle solid tumours iNKT cells have features that may make them useful for treating solid tumours Naturally target cancer Infiltrate tumours and have markers and are prognostic NKG2DL shown promising clinical data for survival CD1d in human solid tumour studies NKG2D i
Slide 26: ALA-105 (CLDN18.2 CAR-iNKT)
ALA-105 (CLDN18.2 CAR-iNKT) A clinically validated target that is expressed in several solid tumour types 26
Slide 27: An off-the-shelf solution for solid tumours
An off-the-shelf solution for solid tumours With ALA’s proprietary cytokine armouring Validated target with high unmet need Novel, proprietary Potential to target a broad range of cancers CLDN18.2-targeting CAR ALA-105 (CLDN18.2 CAR-iNKT) Addresses key CAR-T challenges Efficacy – iNKT cells: • nat
Slide 28: Introducing Claudin 18.2 (CLDN18.2)
Introducing Claudin 18.2 (CLDN18.2) A promising solid tumour target ALA-105 (CLDN18.2 CAR-iNKT) CLDN18.2 overexpression has been Validated target identified in several First monoclonal antibody approved in 2024; First CAR-T for solid types of cancers tumours approved in China in 2026 gastric cancer
Slide 29: Leverage an antibody to create a CLDN18.2-CAR
Leverage an antibody to create a CLDN18.2-CAR Sequence of SPX-101 used to create novel CAR ALA-105 (CLDN18.2 CAR-iNKT) Convert antigen binding Incorporate the CAR sequences into an scFv into Arovella’s platform and format into a CAR The CLDN18.2-binding domains of a monoclonal antibody (SPX-101) wer
Slide 30: Arovella's novel CLDN18.2-targeting CAR is highly active
Arovella’s novel CLDN18.2-targeting CAR is highly active Potent cytotoxicity in iNKT cells improved by armouring with IL-12-TM Killing of Gastric and Pancreatic Cancer Gastric cancer cells Pancreatic cancer cells CLDN18.2 CAR in iNKT cells ALA-105 (CLDN18.2 CAR-iNKT) * * ** ** 100 100 Leads to s
Slide 31: Taking ALA-105 to IND filing
Taking ALA-105 to IND filing ALA is progressing nonclinical development of ALA-105 File IND with the FDA Complete IND-enabling studies ALA-105 (CLDN18.2 CAR-iNKT) Complete Process Development to manufacture ALA-105 Manufacture GMP CLDN18.2 CAR lentivirus Test CLDN18.2 CAR-iNKT cells in mouse models
Slide 32: IL-12-TM (Solid Tumors)
IL-12-TM (Solid Tumors) “Armouring” CAR-iNKT cells
Slide 33: IL-12-TM (Armouring for Solid Tumours)
ARMOURING “Armouring” CAR-iNKT cells IL-12-TM (cytokine technology) enhances CAR-iNKT cell activity in solid tumours IL-12-TM IL-12-TM (Armouring for Solid Tumours) iNKT cells IL-12-TM IL-12-TM is a modified version of IL-12 Expand more 10x more Superior with a membrane anchor that links and survive
Slide 34: Key benefits of IL-12-TM for CAR-iNKT cells
Key benefits of IL-12-TM for CAR-iNKT cells IL-12-TM enhances antitumor activity of CAR-iNKT cells Tumour cells positive for GD2 and were intravenously delivered into mice before treatment with CAR-iNKT cells IL-12-TM (Armouring for Solid Tumours) Mice were treated with: PBS (saline) GD2-CAR
Slide 35: IL-12-TM outperforms IL-15
IL-12-TM outperforms IL-15 IL-12-TM confers superior antitumor activity to CAR-iNKT cells than IL-15 Tumour cells positive for GD2 were intravenously delivered into mice before treatment with CAR-iNKT cells PBS (n=4) GD2-CAR + IL-15 (n=5) IL-12-TM (Armouring for Solid Tumours) Mice were treated
Slide 36: Key benefits of IL-12-TM for CAR-iNKT cells
Key benefits of IL-12-TM for CAR-iNKT cells IL-12-TM increases CAR-iNKT cell numbers and does not get released into the bloodstream Increased CAR-iNKT cell numbers IL-12-TM is not released from CAR-iNKT cells IL-12-TM (Armouring for Solid Tumours) 2,000 iNKT cells/ 100 µL blood 1,500 GD2-CAR GD2-CAR
Slide 37: Arovella's expanding pipeline
Arovella’s expanding pipeline ALA-101 ALA-105 Upcoming Commence phase 1 clinical trial Generate animal model data for Milestones for patients with CD19-positive CLDN18.2 CAR-iNKT cells with lymphoma and leukaemia IL-12 armouring ASX:ALA 37
Slide 38: Summary
Summary FDA-accepted Near-term clinical-stage company milestones ALA-101 entering human trials Clinical batch release, site activation, first patient dosing and initial clinical readouts Differentiated cell Multiple expansion therapy platform CAR-iNKT cells combine Arovella’s opportunities Blood can
Slide 39: Thank You
ASX:ALA Thank You Arovella Therapeutics Email: investor@arovella.com
Slide 40: Appendix - references
Appendix - references 1. https://www.businesswire.com/news/home/20250210311887/en/CAR-T-Cell-Therapy-Market-Industry-Trends-and-Global-Forecasts-to-2035-CD19-and-BCMA-Have-Emerged-as-the-Most-Popular-Target-Antigens- --ResearchAndMarkets.com 2. Zinzi et al., 2023 Pharmacological Research - 10.1016/j
Arovella Therapeutics — Investor Presentation (August 2026) on 6ix